Surgery Partners Inc

Surgery Partners Inc(SGRY)股票分析

$23.240

-0.119 (-0.51%)收盤時

Loading chart…
最高
23.360
開盤
23.260
成交量加權均價
23.27
成交量
3.11M
市值
3.09B
最低
23.200
成交金額
72.25M
企業價值/稅息折舊攤銷前利潤(TTM)
12.15

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals.

AI 分析 of Surgery Partners Inc (SGRY)

買進

Surgery Partners Inc is a good buy right now due to its current price of $15.75, a strong RSI of 75.34 indicating overbought conditions, and a forward P/E ratio of 18.90 suggesting reasonable valuation compared to growth prospects. The stock has shown a positive 5-day change of +7.80%, reflecting recent upward momentum. However, investors should be cautious of the significant $4 billion debt burden, which poses a risk to financial stability.

分析師評級(9)

上檔空間 +13.17%
買進
4 買進
4 持有
1 賣出
目前: 23.24
最低
18.00
平均
26.30
最高
36.00

JPMorgan

2026-09-14

目標價

$15

中性

RBC Capital

2026-08-11

目標價

$19

優於大盤

TD Cowen

2026-08-11

目標價

$19

買進

Cantor Fitzgerald

2026-08-11

目標價

$18

增持

Jefferies

2026-05-06

目標價

$17

買進

估值指標

Surgery Partners Inc(SGRY)目前預期本益比為 588.24,5 年平均預期本益比為 74.57。

預期本益比

嚴重高估
5 年均值 P/E
74.57
目前P/E
588.24
高估
213.67
低估
-64.53

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
15.66
目前EV/EBITDA
12.15
高估
19.94
低估
11.39

預期股價營收比

合理
5 年均值 P/S
1.09
目前P/S
1.08
高估
1.50
低估
0.68

Alphio AI 對 SGRY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%SGRY

$22.84

情境價格

基

基準

基準 · 50%SGRY

$21.90

情境價格

悲

悲觀

悲觀 · 25%SGRY

$21.04

情境價格

持有 SGRY 的大戶

D

Davidson Kempner Capital Management LP

+ 持有SGRY

-6.00%

3個月報酬率

P

Pentwater Capital Management LP

+ 持有SGRY

-6.01%

3個月報酬率

事件時間軸

2026-10-27 (ET)

16:30:00

UBS Downgrades Surgery Partners to Neutral with $23.50 Price Target

07:00:00

StoneX Downgrades Surgery Partners to Hold

2026-10-26 (ET)

17:00:00

Major Averages Rise as Investors Prepare for Earnings Week

14:30:00

Cantor Fitzgerald Downgrades Surgery Partners to Neutral with $23.50 Price Target

12:30:00

Surgery Partners Stock Rises 46.3% to $23.05

資訊

SGRY 常見問題 —— 由 Alphio AI 解答

Surgery Partners, Inc. is a healthcare services company. The Company, through its subsidiaries, owns and operates a national network of surgical facilities and ancillary services. The Company operates through the Surgical Facility segment, which includes the operation of ambulatory surgery centers (ASCs), surgical hospitals, anesthesia services, urgent care facilities and multi-specialty physician practices. Its surgical facilities primarily provide non-emergency surgical procedures across many specialties, including, among others, orthopedics and pain management, ophthalmology, gastroenterology (GI) and general surgery. The Company operates a portfolio of approximately 162 surgical facilities comprised of 175 ASCs and 19 surgical hospitals. The Company is focused on surgical services businesses in the United States, with over 200 locations in 30 states, including short-stay surgical hospitals. It operates in the Healthcare sector (SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC industry).

Surgery Partners Inc is a good buy right now due to its current price of $15.75, a strong RSI of 75.34 indicating overbought conditions, and a forward P/E ratio of 18.90 suggesting reasonable valuation compared to growth prospects. The stock has shown a positive 5-day change of +7.80%, reflecting recent upward momentum. However, investors should be cautious of the significant $4 billion debt burden, which poses a risk to financial stability.

9 analysts cover SGRY: 4 rate it Buy, 4 Hold and 1 Sell. The average price target is 26.30.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易